Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy
GlobeNewswire Inc.
•
•By Greenwich Lifesciences, Inc.
Greenwich LifeSciences provided updates on its Phase III FLAMINGO-01 clinical trial for GLSI-100, an immunotherapy to prevent breast cancer recurrences. The company reported that the 250-patient non-HLA-A*02 arm is fully enrolled with preliminary data showing approximately 80% reduction in recurrence rates. The company is implementing cost reduction measures, expanding to additional sites and countries, and pursuing strategic partnerships while maintaining its ATM financing strategy with a burn rate of approximately $7 million annually.